• Crescendo Reaffirms a new Oncology Focus

News & Views

Crescendo Reaffirms a new Oncology Focus

Dec 01 2015

Crescendo Biologics Ltd, which discovered and developed HumabodyTM  VH therapeutics has announced Dr Kevin Johnson as non-executive Chairman of the Board of Directors. This reinforces a recent strategic move by the company into oncology drug discovery and development, which also saw the appointment of Dr Peter Pack as the new CEO.

Dr. Johnson brings 27 years of antibody development experience, notably as ex-CTO of Cambridge Antibody Technology and ex-CEO of Pangenetics (acquired by Abbott in 2009). Since 2003 he has been on the Life Sciences team of Index Ventures, focusing on drug development companies.

“Kevin is a highly seasoned executive to head up our Board of Directors as we move the focus of the Company into the field of Oncology,” said Peter Pack.  “His past experience is very relevant – from Cambridge Antibody Technologies where he was responsible for its antibody platform technologies to Pangenetics which specialised in taking antibodies from the late research stage through to clinical proof of concept. His input has already proved instrumental to the planning of our new strategy.”

Kevin Johnson added: “Crescendo Biologics has a very promising pipeline in development based on its unique Humabodies™ platform. The Company is at an exciting inflection point, expanding its oncology pipeline by targeting a range of cancer indications with its multi-specific checkpoint modulators and its Humabody™ Drug Conjugates.”

Graziano Seghezzi, Non-Executive Director of Crescendo Biologics, added:
”Kevin’s long-standing interest and experience of drug and antibody development and his expertise in the antibody arena is going to be crucial to us as we grow. On behalf of the Board, I welcome him and look forward to working closely together.”


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

Analytica Anacon India & IndiaLabExpo

Apr 15 2024 Mumbai, India

Analitika Expo 2024

Apr 16 2024 Moscow, Russia

View all events